Compositions and methods for treating neurodegenerative disorders
AssigneeGnt Pharma Co., Ltd.
InventorsJinhwan Lee, Jae Bong Moon, Byoung Joo Gwag
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.
Claims21
A composition comprising a compound of formula (I):
- wherein
- X is selected from CO, SO2 and (CH2)n;
- R1 is selected from hydrogen, C1-C6 alkyl and C1-C6 alkanoyl;
- R2 is selected from hydrogen and C1-C6 alkyl;
- R3 is selected from hydrogen and a C1-C5 acetyl group;
- and
- R4 is selected from a phenyl group, a phenoxy group, and a 5- to 10-membered aryl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C5 alkoxy, and C1-C5 haloalkoxy;
- n is an integer from 1 to 5, inclusive;
- or a pharmaceutically acceptable salt thereof;
- and
- a pharmaceutically acceptable excipient, e.g., suitable for oral administration.
9-11. (canceled)
A method of treating cognitive and/or neurobehavioral impairment, comprising administering to a companion animal in need thereof a compound of formula (I):
- wherein
- X is selected from CO, SO2 and (CH2)n;
- R1 is selected from hydrogen, C1-C6 alkyl and C1-C6 alkanoyl;
- R2 is selected from hydrogen and C1-C6 alkyl;
- R3 is selected from hydrogen and a C1-C5 acetyl group;
- and
- R4 is selected from a phenyl group, a phenoxy group, and a 5- to 10-membered aryl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C5 alkoxy, and C1-C5 haloalkoxy;
- where n is an integer of 1 to 5, inclusive;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.